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Abstract: The amount of irreversible injury on renal allograft biopsy
predicts function, but little is known about the early evolution of this
damage. In a single-center cohort, we examined the relationship between
donor-, recipient-, and transplantation-associated factors and change in a
morphometric index of chronic damage (ICD) between protocol biopsies
performed at implantation and at 2–3 months. We then investigated
whether early delta ICD predicted subsequent biochemical outcomes. We
found little evidence to support diﬀerences between the study group, who
had undergone serial biopsies, and a contemporaneous control group,
who had not. In allografts with serial biopsies (n = 162), there was an
increase in ICD between implantation (median: 2%, IQR:0–8) and 2–
3 months post-transplant (median 8% IQR:4–15; p < 0.0001). Donation
from younger or live donors was independently associated with smaller
early post-transplant increases in ICD. There was no evidence for a
diﬀerence in delta ICD between donation after cardiac death vs.
donation after brain death, nor association with length of cold ischemia.
After adjustment for GFR at the time of the second biopsy, delta ICD
after three months did not predict allograft function at one yr. These
ﬁndings suggest that graft damage develops shortly after transplantation
and reﬂects donor factors, but does not predict future biochemical
outcomes.
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Improvements in the outcomes of kidney trans-
plantation have mainly been conﬁned to preven-
tion of early graft loss. Over the last 20 yr, the
slopes of allograft survival curves from one yr
post-transplant have remained almost parallel
(1, 2). Furthermore, due to the chronic undersup-
ply of donor organs, there has been a recent move
toward the use of “extended criteria” donors and
donation after cardiac death (DCD) with
consequent concerns surrounding the long-term
outcomes for recipients of these kidneys.
The total amount of irreversible histological
damage on protocol biopsies at early time points,
as estimated by Banﬀ criteria for chronic damage
(3–5) or as measured morphometrically (6, 7), is a
predictor of longer-term graft outcomes, and this
damage appears to be established early post-trans-
plantation.
Although previous studies have examined clini-
cal predictors of chronic damage at a single time
point or over many years, little is understood
about the factors surrounding transplantation that
are associated with the early evolution of such
damage, that is, the relationship between clinical
variables and changes in measures of chronic
damage during the ﬁrst post-transplant months.
This is an issue of particular importance in kidneys
from “extended criteria” donors (ECD) or dona-
tion following cardiac death (DCD) as these
allografts are likely to have signiﬁcant levels of
pre-existing chronic damage in the former case and
suﬀer increased warm ischemic injury in the latter.
The use of a quantitative approach to assess dam-
age, made possible by the use of digital analysis
systems, has been explored in an investigation of
recipients of live donor transplants (8) or kidneys
donated following brain death (DBD) (9), but the
risk factors for the early evolution of chronic
damage on protocol biopsy of single-organ kidney
transplants from a cohort receiving kidneys of
diﬀering donor types remain unclear.
Using protocol biopsies performed as a part of
routine clinical care, the aim of this study was to
examine donor and recipient factors associated
with changes in a morphometric measure of
chronic damage over the ﬁrst three post-transplant
months. We then investigated whether the early
change in this same measure was a useful predictor
of graft function at one yr.
Patients and Methods
In this cohort study, adult recipients of solitary
renal allografts under the care of the Royal Free
London NHS Foundation Trust (RFLNHSFT),
transplanted between February 1, 2008, and Octo-
ber 31, 2010, underwent protocol biopsies as part
of their routine clinical care. The unit policy is for
protocol biopsies to be performed at three time
points: 30 min following allograft implantation
(PB0), 6–12 wk post-transplantation (PB1), and
one yr post-transplantation. Only data from the
ﬁrst two are described here, as uptake of the one-yr
biopsy is low (n = 72, 29%) and likely to be heav-
ily inﬂuenced by clinical factors; that is, those
patients with a well-functioning graft are likely to
forego this biopsy. All patients undergoing biopsy
gave informed consent as to the clinical risks and
beneﬁts of the program. The following were con-
sidered contraindication to protocol biopsy: high
bleeding risk, pregnancy, and indicated biopsy
within the last 14 d.
The immunosuppressive protocol was
unchanged for the duration of this study. Induc-
tion therapy consisted of basiliximab (days 0 and
4), methylprednisolone, tacrolimus, and myco-
phenolate mofetil. Maintenance therapy (com-
menced ﬁve d prior to the transplant in recipients
of live donor kidneys) consisted of (i) tacrolimus
adjusted to maintain a trough level of 9–12 lg/L
for the ﬁrst three months and then 6–9 lg/L
(except in cases of delayed graft function where
target trough levels are 6–9 lg/L until graft func-
tion is established); (ii) mycophenolate mofetil 1 g
bd reduced to 750 mg bd after one month;
(iii) prednisolone 20 mg daily for one wk and
10 mg daily for one wk followed by steroid with-
drawal. Acute cellular rejection was treated with
pulsed methylprednisolone and continuation of
oral steroids with the addition of antithymocyte
globulin (ATG) in resistant cases. Acute vascular
rejection was treated with the addition of plasma
exchange where there was an identiﬁable donor-
speciﬁc antibody, plus rituximab in resistant cases.
Patients underwent a preemptive CMV surveil-
lance strategy (except for those enrolled in a clini-
cal trial or considered high risk), receiving antiviral
therapy only where routine samples revealed CMV
antigen levels >1250 copies/mL.
Protocol biopsies were performed by senior
clinicians, under direct vision at implantation or
live ultrasound guidance post-transplantation.
Samples were obtained using either 16-gauge nee-
dles (at implantation) or 18-gauge biopsy needles
(post-transplant) and were examined using a dis-
secting microscope at the bedside to conﬁrm ade-
quate sampling. Biopsies were formalin-ﬁxed,
paraﬃn-embedded, and serially sectioned before
staining using conventional techniques. The mor-
phometric measure, called the index of chronic
damage (ICD), was determined in sections from
PB0 to PB1 (ICD0 and ICD1, respectively) as pre-
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viously described (7). Brieﬂy, on a computerized
image, the area of renal cortex excluding renal cap-
sule was measured in arbitrary units. Areas of
chronic damage, identiﬁed by global sclerosis of
glomeruli, tubular atrophy, interstitial ﬁbrosis,
and/or occluded vessels, were also quantiﬁed. The
amount of damage was expressed as a percentage
of cortical area to the nearest integer.
Donor data were retrieved from NHS Blood and
Transplant (NHSBT). NHSBT deﬁnitions were
used for mismatch level (10). Donor serum creati-
nine concentration from admission was used where
available; otherwise, ﬁrst available creatinine was
obtained. Recipient data were retrieved from elec-
tronic hospital records. Rejection was deﬁned as
per Banﬀ criteria on indication biopsies prior to
PB1 or on that protocol biopsy (or on biopsies at
less than three months for the group not undergoing
PB1). BK nephropathy was deﬁned by the presence
of virus detected by an immunoperoxidase method.
The number of indicated biopsies was the total
number of biopsy attempts prior to the ﬁrst post-
transplant biopsy (or in the ﬁrst three months for
those not undergoing PB1). Serum creatinine val-
ues were obtained from day 56 and day 365 (or the
nearest available measurement subsequent to these
dates) post-transplant eGFR calculated by the 4-
variable MDRD equation (11). All analyses were
performed by allograft, so two patients who both
received a second transplant during the study per-
iod were represented twice although sensitivity
analysis excluding these second grafts did not alter
any of the main ﬁndings.
As not all patients transplanted in the study per-
iod had undergone serial protocol biopsies, we
examined whether there were diﬀerences between
the group who had undergone such biopsies and
the group who had not using the chi-squared test
(Fisher’s exact test for cells with small numbers)
and t-test (Wilcoxon rank-sum test for nonpara-
metric variables). Then, in a sensitivity analysis, we
examined whether inclusion in the biopsy group
was associated with diﬀerences in eGFR at
eight wks or cumulative incidence of rejection over
the follow-up period, after matching using a pro-
pensity score based on donor and recipient charac-
teristics.
We went on to examine the associations between
ICD and clinical variables. ICD scores were posi-
tively skewed at all time points so to examine pre-
dictors of ICD0, and change in ICD (ICD1-ICD0;
delta ICD) scores was divided into equal frequency
tertiles and quartiles, respectively. Univariable
associations between clinical variables and ICD0
or delta ICD were examined using analysis of vari-
ance (ANOVA) (Kruskal–Wallis [K-W] test for
nonparametric variables) and chi-squared test
(Fisher’s exact test for cells with small numbers).
The change in ICD between paired samples was
examined using the Wilcoxon rank-sum test.
For multivariate analysis, we did not group
ECD and DBD donors separately, ﬁrstly to avoid
small cell numbers and also so we could examine
clinical factors that would lead to the deﬁnition of
a donor as ECD (donor serum creatinine
>133 lMol/L; intracerebral hemorrhage, ICH;
donor age) in both DBD and DCD groups. To
identify independent predictors of ICD0 and delta
ICD, we used a logistic regression models and
included exposure variables where we hypothesized
an impact on ICD. For baseline chronic damage,
these were donor type (live, DCD, or donation
after brain death [DBD]), age, sex, ethnic group,
donor serum creatinine>133 lMol/L, ICH,
diabetes mellitus (DM), and cold ischemic time
(CIT; deceased donors only). For change in
chronic damage, these were as above plus recipient
factors: mismatch level, age, sex, ethnic group, pre-
vious transplantation, primary disease, DM, BK
nephropathy, and rejection. Adjustment was made
for the timing of PB1, but otherwise variables were
retained in the models only where there was an
improvement in model ﬁt as demonstrated by a
reduction in the 2 log-likelihood ratio. We also
performed a restricted analysis excluding donors
dying from ICH. Following ﬁtting of the ordinal
logistic model, the proportional odds assumption
was tested for each of the variables in the model
individually. Where this was violated, as in the
model of ICD0, a multinomial logistic approach
was used, and relative risk ratios were reported for
each category. Predicted odds ratios or relative risk
ratios were compared with observed values for
both multivariable models. A further sensitivity
analysis examining change in chronic damage was
carried out using a linear regression model with log
ICD1 adjusted for log ICD0, and although model
ﬁt was poor, the main conclusions, as identiﬁed
using the logistical modeling approach, were
unchanged.
To investigate whether delta ICD might predict
future outcome, we then examined whether this
same measurement (as an explanatory variable)
was associated with biochemical measures of kid-
ney function. First, we examined the relationship
between delta ICD quartile and quartile of GFR at
biopsy. Then, to test the usefulness of the measure
as a predictor of future function, we examined the
association between delta ICD quartile and the
change in eGFR between the time of PB1 and one-
yr post-transplant (eGFR at day 365 after adjust-
ment for eGFR at day 56).
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Summary statistics are presented as
means  standard deviation (or medians with in-
terquartile range for non-normally distributed
variables). Statistical signiﬁcance was accepted as
p < 0.05. This was a descriptive study, and there-
fore, no power calculations were performed. Data
were analyzed in Stata 11 (Stata Corp LP, College
Station, TX, USA).
Results
Cohort
Two hundred and sixty seven patients under fol-
low-up at the renal transplant unit RFLNHSFT
underwent 269 kidney-alone transplants between
February 1, 2008, and October 31, 2010. Six
patients were transplanted elsewhere, so no ICD0
was available. A further 17 allografts were
excluded from further analysis due to nephrectomy
(n = 8), loss to follow-up (n = 2), recipient death
(n = 5), and contraindication to protocol biopsy
(n = 2). Either ICD0 (n = 45) or ICD1 (n = 61) or
both were not available on a further 81 allografts
due to patient refusal (n = 5), multiple recent indi-
cated biopsies (n = 2), or undocumented reasons.
Delta ICD was available for 162 allografts, and
along with three allografts with biopsies that were
technically inadequate, this group (n = 165) was
compared with those who did not undergo both
protocol biopsies (n = 81). The “6–12 wks” post-
transplant protocol biopsies were performed a
median of 56 d (IQR 48–72) following transplanta-
tion. There was a higher prevalence of female
donors, and there were an increased number of
indicated biopsies in the group who did not
undergo serial biopsies, but there were no other
diﬀerences observed between the groups (Table 1).
Speciﬁcally, there were no diﬀerences seen in CIT,
the prevalence of diﬀerent donor types, eGFR, or
biopsy proven rejection. In a sensitivity analysis,
using propensity score matching, no signiﬁcant dif-
ferences were seen in eGFR at eight wk or the
cumulative incidence of rejection between those
undergoing protocol biopsies and those who did
not (data not shown).
Predictors of ICD on implantation biopsy
Overall (including allografts where delta ICD was
not available), median ICD0 was 2% (IQR 0–7).
On univariable analysis, donor age, transplant
type, and donor ethnic group were associated with
tertile of ICD0 (Table 2). On multinomial logistic
regression, there was a higher relative risk ratio of
ICD0 falling in tertile two and three with both
higher donor age and donation following cardiac
death (Table 3). However other donor variables,
including donor ethnic group, were not associated
with tertile of ICD0 in the adjusted model. Fur-
thermore, other than age, inclusion of factors that
would lead to a donor being deﬁned as “extended
criteria” (ICH, serum creatinine >133 lMol/L,
hypertension) did not alter the relative risk ratios.
Most (six of nine) of the donors with DM were in
the highest ICD0 tertile, but as overall numbers
were small, this variable was not included in the
multivariable model.
Predictors of Change in ICD
Overall (including allografts where delta ICD was
not available, n = 188), median ICD1 was 8%
(IQR: 4–15). Restricting the analysis to those sub-
jects for whom delta ICD was available, there was
a small but highly signiﬁcant increase between
biopsies (median increase, 4%; IQR: 1–9). Box and
whisker plots of ICD0 and ICD1 stratiﬁed by
donor type are shown in Fig. 1. A negative delta
ICD was observed in 25 of the 162 allografts.
Univariable associations between clinical vari-
ables and quartile of delta ICD are presented in
Table 4. Transplant type (Fig. 2) and history of
donor ICH along with recipient and donor age
were the only clinical variables associated with
delta ICD. Kidneys transplanted from live donors
showed little change in ICD over time, while kid-
neys from DCD donors were more prevalent in the
higher quartiles of delta ICD. Mean donor age was
higher across increasing quartiles of delta ICD
(p < 0.01 for a trend). Borderline relationships
were found with donor serum creatinine concentra-
tion, donor ethnic group, previous transplantation,
donor DM, and mismatch level, although the
power to detect associations for the latter explana-
tory variables was limited due to small numbers.
Donor age and donor type were the only vari-
ables independently associated with quartile of
delta ICD on multivariable analysis using an ordi-
nal logistic regression model (Table 5). Increasing
donor age was independently associated with
increased odds of a higher quartile delta ICD with
an OR of 1.29 (95% CI: 1.06–1.57) for each decade
over 48 yr. Receiving a kidney from a live donor
was independently associated with lower odds of a
higher delta ICD quartile with an OR of 0.40 (95%
CI: 0.20–0.80) compared with the reference group
of DBD. There was no signiﬁcant increase in odds
associated with receiving a kidney from a DCD vs.
DBD (OR 1.30; 95% CI: 0.62–2.73). Exclusion of
donors dying from ICH did attenuate the diﬀer-
ences in OR between live and DBD donors, sug-
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Table 1. Description of the study cohort and comparison between the groups of allografts for which serial biopsies were not and were per-
formed
All allografts n = 246
Allografts without serial
biopsies n = 81
Allografts with serial
biopsies n = 165 p-Value
Recipient age
Years, mean, SD 49.4 13.8 47.5 15.3 50.2 13.1 NS
Recipient sex
Female n,% 114 46.3 38 46.9 76 46.1 NS
Recipient ethnic group
Asian n,% 51 20.7 19 23.5 32 19.4 NS
Black n,% 54 22.0 13 16.1 41 24.9
Chin/oth/ns n,% 34 13.8 9 11.1 25 15.2
White n,% 107 43.5 40 49.4 67 40.6
Recipient primary disease
Cystic n,% 20 8.1 8 9.9 12 7.3 NS
DM n,% 27 11.0 11 13.6 16 9.7
Dysplastic/reflux n,% 10 4.1 4 4.9 6 3.6
Glomerular n,% 48 19.5 17 21.0 31 18.8
Vasc/isch/hyp n,% 27 11.0 9 11.1 18 10.9
Other n,% 74 30.1 23 28.4 51 30.9
Unknown n,% 40 16.3 9 11.1 31 18.8
Recipient DM
n,% 35 14.2 10 12.4 25 15.2 NS
Previous transplant
n,% 25 11.0 12 14.8 15 9.1 NS
Donor age
Years, mean, SD 48.0 15.8 47.3 16.3 48.3 15.5 NS
Donor sex
Female n,% 102 43.0 39 54.2 63 38.2 0.02a
Donor ethnic group
Asian n,% 19 8.0 6 8.3 13 7.9 NS
Black n,% 17 7.2 5 6.9 12 7.3
Chin/oth/ns n,% 5 2.1 0 0.0 5 3.0
White n,% 196 82.7 61 84.7 135 81.8
Donor creatinine
lMol/L, geo mean, SD 78.3 1.5 75.1 1.5 79.0 1.5 NS
Donor DM
n,% 10 4.2 3 4.2 7 4.3 NS
Donor weight
Kilograms, mean, SD 78.4 16.7 77.6 16.4 78.7 16.8 NS
Donor type
ECD, n,% 64 26.0 42 25.5 22 27.2 NS
DBD, n,% 17 6.9 11 6.7 56 7.4
DCD, n,% 71 28.9 20 24.7 51 30.9
Live, n,% 94 38.2 33 40.7 61 37.0
Mismatch level
1, n,% 19 8.0 4 5.6 15 9.1 NS
2, n,% 52 21.9 14 19.4 38 23.0
3, n,% 137 57.8 44 61.1 93 56.4
4, n,% 29 12.2 10 13.9 19 11.5
CIT (deceased donor only)
Hours, mean, SD 16.1 4.5 16.4 4.1 16.0 4.6 NS
Indicated biopsies
n, median, IQR 1 0–2 1.5 1–2.5 0 0–2 0.004b
Rejection
n,% 24 9.8 7 8.6 17 10.3 NS
BK virus
n,% 3 1.3 1 1.4 2 1.2 NS
Recipient eGFR at day 56
mL/min/1.73 m2 median (IQR) 47.3 35.6- 59.7 50.1 35.7–65.4 46.4 33.8–57.6 NS
Rejection and indicative biopsies were counted up to the time of first post-transplant protocol biopsy in the group with protocol biopsies and to 12 wks in
the group not undergoing a biopsy at this time point. Percentages represent column percentage. Numbers of deceased donors with CIT data: total 129; 38
and 91 in each group, respectively.
CIT, cold ischemic time; DM, diabetes mellitus; dysplastic, dysplastic kidneys; vasc/isch/hyp, renal disease classified as renovascular or due to chronic
renal ischemia; ECD, extended criteria donor; DBD, donation after brain death (excluding ECD); DCD, donor after cardiac death; DBD, donor after brain
death; SD, standard deviation.
aBy chi-squared.
bBy Wilcoxon rank-sum test.
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gesting that this may be one factor responsible for
the diﬀerences seen in delta ICD between donor
types (Table 5). Although the prevalence of donor
DM appeared higher in the higher quartiles of
delta ICD, again low numbers mean that this vari-
able was not included in the ﬁnal model. Other
donor-, recipient-, and transplant-associated vari-
ables did not improve model ﬁt. In particular, no
Table 2. Clinical variables stratified by ICD tertile at implantation
ICD on implantation biopsy
p-ValueZero n = 72 Moderate n = 68 High n = 78
ICD
%, median, range 0 0–0 2 1–4 9 5–46
Donor age
Years, mean, SD 41.3 14.6 46.3 14.5 57.6 11.1 <0.001c
Donor sex
Female n,% 35 48.6 28 41.2 28 36.8 NS
Donor ethnic group
Asian n,% 8 11.1 9 13.2 1 1.3 0.02d
Black n,% 6 8.3 3 4.4 5 6.6
Chin/oth/ns n,% 2 2.8 3 4.4 0 0.0
White n,% 56 77.8 53 77.9 70 92.1
Donor creatinine
lMol/L, geo mean, SD 75.9 1.4 77.2 1.5 79.6 1.4 NS
Donor DM
n,% 2 2.8 1 1.5 6 8.1 NS
Donor weight
Kilograms, mean, SD 77.7 19.5 78.1 14.2 81.5 13.0 NS
Donor ICH
n,% 22 30.6 17 25.0 26 33.3 NS
Donor type
DBD n,% 29 40.3 15 22.1 27 34.6 0.001a
DCD n,% 11 15.3 21 30.9 33 42.3
Live n,% 32 44.4 32 47.1 18 23.1
CIT (DCD and DBD only)
Hours, mean, SD 16.1 4.7 16.2 5.5 16.1 4.4 NS
Numbers of deceased donors with CIT data: total 115; 35, 32, and 48 in each group, respectively. Abbreviations and characters as Table 1.
CIT, cold ischemic time; DBD, donated after brain death; DCD, donation after cardiac death; DM, diabetes mellitus; ICD, index of chronic damage; ICH,
intracerebral hemorrhage
cBy analysis of variance (ANOVA).
dBy Fisher’s exact test.
Table 3. Multinomial logistic regression model of ICD at baseline
Risk ratio relative to lowest tertile ICD0
Middle Highest
RRR 95% CI RRR 95% CI
Donor type
DBD Reference Reference
DCD 3.71 1.40 9.82 3.96 1.49 10.51
Live 1.93 0.87 4.33 0.77 0.31 4.32
Donor age
Per decade
>48 yrs
1.29 1.01 1.64 2.47 1.82 3.36
Generalized logistic regression model used as proportional odds
assumption violated for the above variables across tertiles of ICD0.
ICD0, ICD at implantation biopsy; RRR, relative risk ratio; CI, confidence
interval; DBD, donation after brain death; DCD, donation after cardiac
death; ICD, index of chronic damage.
**** 
Fig. 1. Index of chronic damage (ICD) at implantation and
ﬁrst protocol biopsy. Box and whisker plot of ICD scores at
implantation (PB0) and ‘6–12 wk’ biopsy (PB1) stratiﬁed by
donor type. Centre bar: median; Boxes: 25th and 75th centiles;
Whiskers: upper and lower adjacent values; Dots: outliers.
****p < 0.001 by Wilcoxon signed-rank test. Includes allo-
grafts only where serial ICD was available.
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Table 4. Clinical variables stratified by quartile of delta ICD on serial protocol biopsies
Quartile of delta ICD
p-Value1 (n = 36) 2 (n = 36) 3 (n = 45) 4 (n = 45)
Delta ICD
%, Median, range 2 11 to 0 2 1 to 3 5 4 to 8 13 9 to 44
Recipient age
Years, mean, SD 52.4 11.5 47 14.5 47.2 13.4 54.1 12.1 0.023c
Recipient sex
Female n,% 19 52.8 11 30.6 21 46.7 22 48.9 NS
Recipient ethnic group
Asian n,% 5 13.9 6 16.7 11 24.4 8 17.8 NS
Black n,% 7 19.4 5 13.9 11 24.4 17 37.8
Chin/oth/ns n,% 6 16.7 10 27.8 5 11.1 4 8.9
White n,% 18 50.0 15 41.7 18 40.0 16 35.6
Recipient primary disease
Cystic n,% 2 5.6 3 8.3 3 6.7 4 8.9 NS
Dm n,% 3 8.3 4 11.1 5 11.1 3 6.7
Dysplastic/reflux n,% 1 2.8 2 5.6 2 4.4 1 2.2
Glomerular n,% 9 25.0 8 22.2 7 15.6 6 13.3
Vasc/isch/hyp n,% 4 11.1 2 5.6 2 4.4 10 22.2
Other n,% 14 38.9 10 27.8 14 31.1 12 26.7
Unknown n,% 3 8.3 7 19.4 12 26.7 9 20.0
Recipient DM
n,% 6 16.7 5 13.9 7 15.6 6 13.3 NS
Previous transplant
n,% 5 13.9 2 5.6 7 15.6 1 2.2 0.10d
Donor age
Years, mean, SD 44.3 17.3 46.6 16.0 48.2 12.5 53.4 13.9 0.043c
Donor sex
Female n,% 15 41.7 15 41.7 18 40.0 13 28.9 NS
Donor ethnic group
Asian n,% 3 8.3 7 19.4 3 6.7 0 0.0 NS
Black n,% 3 8.3 3 8.3 2 4.4 4 8.9
Chin/oth/ns n,% 1 2.8 1 2.8 1 2.2 2 4.4
White n,% 29 80.6 25 69.4 39 86.7 39 86.7
Donor creatinine
lMol/L, geo mean, SD 72.4 1.4 84.2 1.4 75.3 1.3 86.3 1.6 0.10c
Donor DM
n,% 0 0 0 0 2 4.4 4 9.1 0.10d
Donor weight
Kilograms, mean, SD 77.4 17.4 78.5 16.3 79.7 17.1 80.4 14.7 NS
Donor type
ECD n,% 5 13.9 6 16.7 12 26.7 18 40.0 <0.001d
DBD n,% 6 22.2 3 8.3 1 2.2 0 0
DCD n,% 8 22.2 6 16.7 15 33.3 21 46.7
Live n,% 17 47.2 21 58.3 17 37.8 6 13.3
Donor ICH
n,% 5 13.9 6 16.7 16 35.5 19 42.2 0.009a
Mismatch level
1 n,% 4 11.1 2 5.6 7 15.6 2 4.4 0.11d
2 n,% 8 22.2 10 27.8 10 22.2 9 20.0
3 n,% 19 52.8 19 52.8 28 62.2 26 57.8
4 n,% 5 13.9 5 13.9 0 0.0 8 17.8
CIT (DCD and DBD only)
Hours, mean, SD 16.1 5.3 15.8 4.5 15.5 3.8 16.0 5.1 NS
Rejection
n,% 5 13.9 5 13.9 6 13.3 7 15.5 NS
BK virus
n,% 0 0 1 2.9 0 0 1 2.2 NS
Recipient eGFR at day 56
mL/min/1.73 m2 median (IQR) 51.9 30.7–61.2 50.9 43.7–60.7 46.8 40.5–57.0 37.8 28.0–50.0 <0.001e
Recipient eGFR at day 365
mL/min/1.73 m2 median (IQR) 52.2 40.9–73.8 52.6 40.9–73.8 51.9 41.6–59.1 45.1 35.0–52.1 0.04e
Numbers of deceased donors with CIT data: total 88; 15, 14, 27, and 32 in each group, respectively. Rejection was defined by a histologically proven epi-
sode of rejection prior to the protocol biopsy. Number of allografts with one-yr creatinine: 127. Abbreviations and characters as Tables 1 and 2.
CIT, cold ischemic time; DBD, donation after brain death; DCD, donation after cardiac death; DM, diabetes mellitus; ECD, extended criteria donor; ICD,
index of chronic damage; ICH, intracerebral hemorrhage.
eBy Kruskal–Wallis test.
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associations were seen between episodes of rejec-
tion or length of CIT (in deceased donors only)
and delta ICD.
Associations between delta ICD and biochemical
measures of kidney function
There was a strong association between delta ICD
and eGFR at day 56 (Table 4). There was also an
association between delta ICD and quartile of
eGFR at day 365 on multivariate testing (adjusted
for episodes of rejection, recipient age, ethnic
group, sex, and diabetes) when biochemical kidney
function at the time of second biopsy was not
included in the model. To test whether early ﬁbro-
sis would be a useful predictor of future allograft
function, we examined whether this measure was
associated with the change in eGFR between day
56 and day 365. We found no association between
delta ICD and change in kidney function between
ﬁrst post-transplant protocol biopsy and one yr
post-transplant (quartile of eGFR at day 365
adjusted for quartile of eGFR at day 56; p = 0.74).
Addition of potential confounders to the model
(rejection, recipient factors) did not alter the lack
of association.
Discussion
In this study, we describe the clinical associations
of early changes in chronic damage on protocol
biopsies performed as a part of a routine clinical
care. Although several other studies have examined
the prevalence of chronic damage in routine biopsy
samples, to our knowledge, this is the ﬁrst one to
examine early change in ICD outside a clinical trial,
in a cohort including transplants from donors after
cardiac and brain death, as well as live donors.
As with all studies of this type, a major concern
is whether patients undergoing protocol biopsies
are representative of the cohort of transplant
patients as a whole. Therefore, we compared clini-
cal variables in the group undergoing both proto-
col biopsies with the group undergoing only one or
neither. We could only detect diﬀerences in donor
sex and number of indicated biopsies. The higher
number of indicated biopsies in the group not
undergoing protocol biopsies may reﬂect causation
(i.e., patients do not undergo protocol biopsies
after a recent indication biopsy) or reverse causa-
tion (i.e., clinicians are more likely to refer for
biopsy where there has not been a recent protocol
biopsy). Reassuringly rates of biopsy proven rejec-
tion were no diﬀerent, suggesting that our analysis
of change in ICD is not restricted to a selected
group of patients in this context. The reasons
underlying lower numbers of female donors in the
protocol biopsy group are less clear, but it could
be that there are diﬀerences in transplant course in
recipients of kidneys from female donors (12).
Overall, these ﬁndings suggest that the cohort in
whom we examined delta ICD is broadly reﬂective
of the transplant population followed up at our
institution during the same time period.
Donor age was independently associated with
ICD0 underlining the well-recognized importance
of this variable in considering the suitability of
organs for transplantation. Furthermore, DCD
kidneys had a higher baseline ICD independent of
age, which may reﬂect a diﬀerence in the underly-
ing clinical characteristics of donors of kidneys of
these types accepted at our institution. No diﬀer-
ences in baseline ICD were observed between
Fig. 2. Prevalence of donor types amongst quartiles of delta
index of chronic damage (ICD). Unadjusted for other clinical
variables. ***p < 0.005.
Table 5. Multivariable ordinal logistic regression model of delta ICD
quartile on serial protocol biopsies
All donors n = 162
Donors with COD ICH
excluded n = 116
OR 95% CI OR 95% CI
Donor type
DBD Reference Reference
DCD 1.30 0.62 2.73 2.90 1.00 8.39
Live 0.40 0.20 0.80 0.78 0.30 1.95
Donor age
Per decade
>48 yrs
1.29 1.05 1.57 1.33 1.05 1.60
Adjusted for timing of second biopsy (days since transplant). Model
meets proportional odds assumptions.
COD, cause of death, OR, odds ratio; CI, confidence interval; DBD, dona-
tion after brain death; DCD, donation after cardiac death; ICD, index of
chronic damage; ICH, intracerebral hemorrhage.
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kidneys from live donors and DBD after adjust-
ment for donor age. Others have reported associa-
tions between early changes in ﬁbrosis and
diabetes, rejection, and kidneys from male donors
(9). We observed trends with the ﬁrst two of these
risk factors and delta ICD in our cohort, but may
have been underpowered to detect signiﬁcant asso-
ciations. Furthermore, kidneys from female donors
made up less than 30% of those allografts in the
highest delta ICD quartile compared with more
than 40% in the lowest three quartiles; however,
this association did not reach statistical signiﬁ-
cance using our approach.
Younger donor age and live donation were
independently associated with reduced odds of
higher delta ICD. As age is known risk factor for
failure to recover from acute kidney injury (13), it
might be expected to impact on recovery from
transplantation-associated ischemia–reperfusion
injury. In one similar study, a similar association
was found on univariable testing (9). Another
recent study did not observe a similar association
with donor age (8); this may be because this inves-
tigation was restricted to live donors, where the
increase in ICD is not marked, limiting the power
to detect any relationship. Although live donors
are often younger than DBD or DCD, the associ-
ation of live donation with lower delta ICD was
independent of donor age.
Overall, there was a small, but highly signiﬁcant
increase in ICD between biopsies. This increase in
chronic damage in our cohort appears consistent
with what has been reported in other studies [(8),
(9)]. This early increase in chronic damage suggests
that the process of transplantation itself leads not
only to an acute kidney injury, but also to irrevers-
ible damage detectable at 2–3 months.
Despite diﬀerences in ICD at implantation, there
was no evidence for a diﬀerence in delta ICD
betweenDBD andDCD after adjustment for donor
age, suggesting that although kidneys from DCD in
our cohort may have higher levels of chronic dam-
age prior to transplantation, the post-transplant
progression of this damage is similar between these
two donor types. We also found no evidence that
either CIT (within the range of CIT seen in deceased
donors) or early acute rejection was associated with
delta ICD. It is impossible to conﬁdently separate
the impact of CIT from donor type in a study of this
design, but these data suggest that there may be
non-ischemic mediators of the association between
live donors and lower delta ICD. The attenuation
of the diﬀerences between live and DBD donors
after exclusion of donors dying from ICH may
implicate this cause of donor death in aggravated
transplantation-associated allograft injury and is
consistent with the worse medium-term outcomes
observed in kidneys transplanted from such donors
(14). Our cohort included too few donors with DM
to draw adequate conclusions as to any association
between this risk factor and delta ICD; however,
with the increasing use of diabetic donors, this
aspect of donor selection would merit further inves-
tigation.
We examined associations between delta ICD
(as the explanatory variable) and eGFR, both at
the time of second biopsy and at one yr. Unsur-
prisingly, delta ICD was associated with eGFR at
both time points. These ﬁnding are similar to those
reported by Servais and colleagues (9). However,
change in ICD between implantation and ﬁrst
post-transplantation biopsy was not additionally
informative of biochemical outcome at one yr (a
surrogate for graft loss (2)) over and above an
eGFR measured at the time of the latter biopsy.
This analysis does have potential for confounding
as clinicians were aware of ICD scores and may
have altered patient management accordingly, and
the small numbers of transplants lost in the period
between ﬁrst post-transplant biopsy and end of fol-
low-up mean that we are unable to examine hard
outcomes such as graft failure. However, these
ﬁndings do suggest that although early change in
chronic damage reﬂects past insults, this measure is
unlikely to provide useful information (above rou-
tine biochemical measures) on the future trans-
plant course as judged by change from eight-wk to
one-yr eGFR.
Almost 16% of serial protocol biopsies demon-
strated a negative delta ICD. Areas of chronic
damage are not thought to recover, so these values
are unlikely to represent true changes. A similar
ﬁnding has been reported elsewhere (15), and as
interobserver variability and intra-observer vari-
ability in the reporting of ICD have been found to
be low (7), negative scores are likely to reﬂect sam-
pling variation. This implies that although poten-
tially a useful research tool, for an individual, even
serial ICD measurements are likely to be of limited
utility except perhaps for very high values (7).
In addition to those mentioned above, our study
has several other weaknesses. Although we exam-
ined, and found little evidence for, diﬀerences
between the group undergoing protocol biopsies
and those who did not, we cannot exclude the pos-
sibility that we have examined a selected group of
patients. All our patients were from a single center,
and therefore, our conclusions may not be general-
izable. Furthermore, we did not examine our biop-
sies for inﬂammation in scarred areas, a ﬁnding
that has been reported to be a useful predictor of
adverse graft outcomes (4). Although, to our
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knowledge, this is the largest study examining
changes in ICD in recipients of kidneys from unse-
lected donors, it is possible that it was underpow-
ered to detect all the important relationships of
delta ICD. However, with more than 50 trans-
plants of each donor type, we would expect to
identify most clinically relevant associations.
In summary, this study demonstrated an early,
small, but measurable increase in irreversible dam-
age in allograft kidneys over the ﬁrst three months
following transplantation. This increase in chronic
damage was associated with donor age. Further-
more, transplantation from a live donor was asso-
ciated with a smaller increase in ICD. The routine
clinical value of measurement of chronic damage is
unclear due to both the potential for sampling vari-
ation and the observation that the early increase in
histological damage appears to reﬂect past insults,
but not future course as judged by biochemical
change in function over the following nine months.
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